Hipertansif ve hipertansif olmayan kronik obstrüktif akciğer hastalığı olan bireylerde fonksiyonel egzersiz kapasitesinin karşılaştırılması

Year 2017, Volume: 4 Issue: 1, 26 - 32, 30.03.0017

İsmail Özsoy Buse Özcan Kahraman Serap Acar Sevgi Özalevli Atila Akkoçlu Sema Savcı

Abstract

Amaç: Çalışmada, hipertansif ve hipertansif olmayan kronik obstrüktif akciğer hastalığı (KOAH) olan bireylerde fonksiyonel
egzersiz kapasitesinin karşılaştırılması amaçlandı.

Yöntem: Çalışmaya, Obstrüktif Akciğer Hastalıklarına Karşı Küresel İşbirliği (GOLD) kriterlerine göre tanısı konmuş, 22
hipertansif olmayan ve 21 hipertansif toplam 43 evre I-IV stabil KOAH’lı birey dahil edildi. Katılımcıların demografik ve klinik
bilgileri, solunum fonksiyon testi sonuçları, semptom skorları (Modifiye Tıbbi Araştırma Kurulu Dispne Skalası ve KOAH
Değerlendirme Testi) ve altı dakika yürüme testi (6DYT) değerleri kaydedildi.

Bulgular: İki grup; demografik bilgiler, sigara maruziyeti, alevlenme hikayesi, solunum fonksiyon testi sonuçları ve semptom
skorları açısından benzerdi (p>0.05). Hipertansif KOAH’lı bireylerin 6DYT mesafeleri istatistiksel olarak hipertansif olmayan
bireylere göre daha düşük bulundu (p<0.05). Başlangıç, bitiş hemodinamik ve vital bulguları ve iki değer arasındaki farkı iki
grupta benzerdi (p>0.05).

Sonuç: KOAH’a eşlik eden hipertansiyon fonksiyonel egzersiz kapasitesini sınırlandırmaktadır. Submaksimal seviyede kalan
egzersiz testlerinde, hipertansif KOAH’lı bireyler hipertansif olmayanlara benzer hemodinamik ve vital yanıtlar vermektedir.
Komorbiditelerin eşlik ettiği heterojen bir hastalık olan KOAH’ta, hipertansiyonun fonksiyonel egzersiz kapasitesini ve egzersiz
eğitim programlarının yapılandırılmasını etkileyebileceği düşünülmelidir.

Keywords

KOAH, Hipertansiyon, Fonksiyonel egzersiz kapasitesi.

Comparison of functional exercise capacity in chronic obstructive pulmonary disease individuals with hypertensive and non-hypertensive

Abstract

Purpose: In the study, it was purposed to compare functional exercise capacity in chronic obstructive pulmonary disease
(COPD) individuals with hypertensive and non hypertensive.

Methods: Twent-two non-hypertensive and 21 hypertensive patients a total of 43 with stage I-IV stable COPD patients who
were diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria were included.
Participants' demographic and clinical information, pulmonary function test results, symptom scores (Modified Medical
Research Council Dyspnea Scale and The COPD Assessment Test), and six-minute walk test (6MWT) values were recorded.

Results: Demographic data, smoking exposure, exacerbation history, pulmonary function test results, and symptom scores
were similar between the two groups (p>0.05). The 6MWT distance of individuals with hypertensive COPD were statistically
lower than those of non-hypertensives (p<0.05). Initial and end values and the change in hemodynamic values and vital
findings were similar in both groups (p>0.05).

Conclusion: Hypertension associated with COPD limits functional exercise capacity. In exercise tests on submaximal levels,
individuals with hypertensive COPD respond similar hemodynamic and vital responses with non-hypertensive COPD. It should
be considered that hypertension may affect functional exercise capacity and structuring exercise training programs in COPD, a
heterogeneous disease accompanied by comorbidities.

Keywords

COPD, Hypertension, Functional exercise capacity.

References

• 1. Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management, and Prevention. A Guide for Health Care Professionals. 2017 Report. www.goldcopd.org.
• 2. Mannino DM, Higuchi K, Yu TC, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138-150.
• 3. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet. 2012;380(9859):2055-2058.
• 4. Corlateanu A, Covantev S, Mathioudakis AG, et al. Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease. Respir Investig. 2016;54(6):387-396.
• 5. Fumagalli G, Fabiani F, Forte S, et al. INDACO project: COPD and link between comorbidities, lung function and inhalation therapy. Multidiscip Respir Med. 2015;10(1):4.
• 6. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10(1):24.
• 7. Yeo J, Karimova G, Bansal S. Co-morbidity in older patients with COPD-its impact on health service utilisation and quality of life, a community study. Age Ageing. 2006;35(1):33-37.
• 8. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-61.
• 9. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-38.
• 10. Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-639.
• 11. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871-88.
• 12. Park HJ, Leem AY, Lee SH, et al. Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey. Int J Chron Obstruct Pulmon Dis. 2015;10:1571.
• 13. Battaglia S, Basile M, Scichilone N, et al. Prevalence of co-morbidities and severity of COPD. COPD. 2015;12(4):390-394.
• 14. Honeyman P, Barr P, Stubbing D. Effect of a walking aid on disability, oxygenation, and breathlessness in patients with chronic airflow limitation. J Cardiopulm Rehabil. 1996;16(1):63-67.
• 15. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376-84.
• 16. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-68.
• 17. Bestall J, Paul E, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-586.
• 18. Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med. 2007;101(3):399-410.
• 19. Jones P, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648- 54.
• 20. Yorgancıoğlu A, Polatlı M, Aydemir O, et al. KOAH değerlendirme testinin Türkçe geçerlilik ve güvenilirliği. Tuberk Toraks. 2012;60(4):314-320.
• 21. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
• 22. Wilson RC, Jones P. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci. 1989;76(3):277-82.
• 23. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. American journal of respiratory and critical care medicine. 1998 Nov;158(5 Pt 1):1384-7.
• 24. Erdfelder E, Faul F, Buchner A. GPOWER: A general power analysis program. Behavior Research Methods, Instruments, & Computers. 1996;28(1):1-11.
• 25. Waatevik M, Johannessen A, Hardie JA, et al. Different COPD disease characteristics are related to different outcomes in the 6-minute walk test. COPD. 2012;9(3):227-234.
• 26. Pepin V, Saey D, Laviolette L, et al. Exercise capacity in chronic obstructive pulmonary disease: mechanisms of limitation. COPD. 2007;4(3):195-204.
• 27. Nici L. Mechanisms and measures of exercise intolerance in chronic obstructive pulmonary disease. Clin Chest Med. 2000;21(4):693-704.
• 28. O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):770-777.
• 29. Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849-857.
• 30. Aliverti A, Macklem PT. Last Word on Point: Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation. J Appl Physiol (1985). 2008 Aug;105(2):763.
• 31. O’Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol (1985). 2008;105(2):753-5; discussion 5-7.
• 32. Andrianopoulos V, Holland AE, Singh SJ, et al. Six-minute walk distance in patients with chronic obstructive pulmonary disease: Which reference equations should we use? Chron Respir Dis. 2015;12(2):111-119.
• 33. Britto RR, Probst VS, Andrade AF, et al. Reference equations for the six-minute walk distance based on a Brazilian multicenter study. Braz J Phys Ther. 2013;17(6):556-563.
• 34. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7(5):335-346.
• 35. Ince DI, Savci S, Arikan H, et al. [Cardiac autonomic responses to exercise testing in patients with chronic obstructive pulmonary disease]. Anadolu Kardiyol Dergi. 2010;10(2):104-11.
• 36. Ganju AA, Fuladi AB, Tayade BO, et al. Cardiopulmonary exercise testing in evaluation of patients of chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci. 2011;53(2):87-91.